In plain words
RSVpreF is a vaccine against respiratory syncytial virus, or RSV, given during pregnancy. It is usually given between 32 and 36 weeks, and it passes antibodies to the baby, which protect the baby in the first months of life. RSV is a common cold-like virus that can cause serious lung infection in babies. A newborn can also receive a separate antibody shot instead, called . Your provider can explain which option fits your timing. Some people have soreness at the injection site or a short fever after vaccination. A baby with trouble breathing, blue lips, or poor feeding needs care right away, and severe breathing trouble is a call to 911.
The deeper version
RSVpreF (Abrysvo) is a bivalent prefusion F protein subunit vaccine licensed for maternal administration at 32 to 36 weeks of gestation during the RSV season, protecting infants through transplacental antibody transfer. The CDC's Advisory Committee on Immunization Practices recommended maternal RSVpreF in 2023. The AAP Red Book presents it alongside infant monoclonal antibody (nirsevimab) as alternatives for the first season. Pregnancy trials showed efficacy against severe lower respiratory tract disease in infants in the early months after birth, with efficacy varying by season and time from vaccination. Preterm birth was tracked as a safety outcome in trials, and surveillance continues. The controversy centers on timing and season, and on which product to use when both are available.
Where it comes up
- Holidays, travel, and events with a newbornSupport, Home, and Village
- Vaccines: the baby's schedule and who around the babyBaby Basics
- Visitors and boundariesSupport, Home, and Village
What mothers here say about RSVpreF
No one has posted under this term yet.
Sources
- Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices — Recommendations for maternal RSV vaccination and infant nirsevimab (2023)
- American Academy of Pediatrics — Red Book: Report of the Committee on Infectious Diseases, current edition